Stryker announced the global commercial launch of the new Trevo ProVue Retriever. According to a company release, this is the first clot removal device fully visible during the procedure for precise positioning within the clot and optimised clot retrieval in patients experiencing acute ischaemic stroke. Previous technology only provided visibility to the edges of the device.
KALAMAZOO, Mich., Nov. 8, 2012 /PRNewswire/ -- Stryker announced today the global commercial launch of the new Trevo® ProVue Retriever. The Trevo ProVue Retriever is the first clot removal device fully visible during the procedure for precise positioning within the clot and optimized clot retrieval in patients experiencing acute ischemic stroke. Previous technology only provided visibility to the edges of the device.
Asahi Intecc has announced the launch of Asahi Chikai and Asahi Chikai10 neurovascular guidewires in the USA and Europe and will begin promotion at the Live Interventional Neuroradiology Conference (LINC, Houston, USA, 11–13 December).
OREM, Utah, Nov. 1, 2012 /PRNewswire/ -- sBioMed, an emerging leader in infection control, announced today that Stephen P. MacMillan, former Chairman and CEO of Stryker, has joined the company as Chief Executive Officer and become an owner of the company.
Phenox GmbH announced that the p64 Flow Modulation Device has received the CE mark approval for commercialisation within the European Union. Hermann Monstadt, managing director at phenox, Bochum, Germany, said: “This approval supports our strategy of moving neurovascular therapies forward through technological innovation and adds to our product portfolio in a way that supports physicians with better tools and as a result provide additional benefits to patients with complex brain aneurysms.”
Just one month ago, Kevin Lobo took over the top spot at medical device maker Stryker Corp. (NYSE:SYK) On Monday, he explained the $8.5 billion corporation s innovation strategy moving forward in his first public appearance as CEO at Cleveland Clinic s Medical Innovation Summit.
Madrid, Octubre de 2012.- Un equipo multidisciplinar del Clínico San Carlos integrado por neurocirujanos, neurorradiólogos vasculares intervencionistas y neurólogos han tratado con éxito a 13 pacientes con malformaciones vasculares cerebrales de alta complejidad, según queda patente en los trabajos publicados en dos revistas internacionales científicias: British Journal of Neurosurgery y Acta Neurologica Scandinavica.
Acandis has announced CE mark approval for its Acandis Aperio 1.9F Thrombectomy System, a next-generation self-expanding blood clot retrieval system used to treat patients with ischaemic strokes.
A study, led by Willem van Zwam, Maastricht University Medical Centre, Maastricht, The Netherlands, published ahead of print in the eJournal of the European Society of Minimally Invasive Neurological Therapy (EJMINT) investigated whether contrast enhanced magnetic resonance angiography (CEMRA) could be an alternative in diagnosing intracranial aneurysms in patients presenting with subarachnoid haemorrhage compared with computed tomographic angiography (CTA).
Barcelona, octubre de 2012.- El grupo de investigación en enfermedades neurovasculares del Vall d’Hebrón Institut de Recerca (VHIR) es el único participante español en el mayor estudio genético sobre ictus realizado a nivel mundial. El trabajo ha estudiado el código genético de más de 72.000 personas entre enfermos y controles y concluye que la clasificación de los ictus según su causa va más allá de la propia enfermedad y se traduce también en claras diferencias genéticas entre los tres subtipos de ictus isquémicos conocidos. Estos hallazgos tendrán, a la larga, un gran impacto clínico, pues cambian la forma de ver el ictus pero, sobre todo, son la puerta de acceso a la búsqueda de dianas terapéuticas específicas para cada uno de estos subtipos. El estudio se ha publicado en la revista The Lancet Neurology y se trata de un estudio multicéntrico y sin precedentes.
Granada, octubre de 2012.- “Andalucía sigue a la cola en la atención al Ictus”. Así lo ha manifestado el doctor Santiago Cousido, presidente de la Sociedad Andaluza de Neurología (SAN) al concluir un coloquio sobre esta enfermedad en el marco de la XXXV Reunión Anual, celebrada en el Hotel Abades Nevada Palace.
Brett Kissela, University of Cincinnati College of Medicine in Ohio, USA, and colleagues have found that stroke incidence may be affecting younger adults. The study is published in the 10 October online issue of Neurology.
On 16 October, Stryker announced a definitive agreement to acquire Surpass Medical. This privately-held company develops next-generation flow diversion stent technology to treat brain aneurysms using a unique mesh design and delivery system.
Neuralstem has reported positive clinical outcomes for Neuralstem’s NSI-566 spinal cord-derived neural stem cell line in a rat model of ischaemic stroke. Data has shown significant improvement in both motor and neurological tests in the stem cell-treated rats.
October 16, 2012—Stryker Corporation (Kalamazoo, MI) announced a definitive agreement to acquire Surpass Medical, Ltd. (Tel Aviv, Israel), which is developing and commercializing next-generation flow diversion stent technology for the treatment of brain aneurysms. Surpass was founded in 2005 in Tel Aviv, with manufacturing and research and development facilities in Miramar, Florida.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos